Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Devices and advanced therapies

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Medicines come first, and for most people they are enough. A minority benefit from a device, and a smaller number reach the point where replacing or supporting the pump is the question.

These decisions are made after several months of full medical treatment, because many hearts improve enough on medicines that a device is no longer needed.

Related pages: Heart failure

The bottom line

What we know
  • ICDs prevent sudden death from dangerous rhythms in selected patients.
  • Cardiac resynchronisation helps people with a wide QRS and persistent symptoms.
  • Device decisions follow at least three months of optimised medicines.
  • LVADs and transplant are options for advanced heart failure in selected people.
  • Palliative care improves symptoms and quality of life and is not only for the end of life.
What is still open
  • Who benefits most from an ICD in the modern treatment era.
  • How to select patients for resynchronisation more precisely.
  • How to expand access to advanced therapies equitably.

The story, step by step

  1. 1. ICDs ()
  2. 2. Resynchronisation ()
  3. 3. Fixing the plumbing ()
  4. 4. Advanced therapies ()
  5. 5. Palliative care ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

Preventing sudden death

Review of many studies

What happens

For dangerous rhythms, not for pumping.

What the research shows

  • An implantable cardioverter defibrillator monitors the rhythm and delivers a shock if a life-threatening ventricular arrhythmia occurs.
  • It is considered when ejection fraction remains at or below 35 percent after at least three months of full medical treatment, with reasonable life expectancy.
  • It does not improve how the heart pumps or how a person feels. It prevents one specific mode of death.
  • Many devices also pace, and modern ones attempt to pace the rhythm back to normal before delivering a shock.
  • Shocks are painful and distressing, and anxiety after a shock is common and worth discussing.
  • The device can be deactivated, which is a legitimate choice near the end of life and should be discussed before it becomes urgent.

Why it matters

Waiting three months on full treatment matters: ejection fraction improves enough in a substantial share of people that the device is no longer indicated.

What's still uncertain

  • Who benefits least now that medical therapy is stronger.
  • The best approach to deactivation conversations.

Read more

Next: Resynchronisation

Part 2 of 5

CRT pacing

Review of many studies

What happens

Making the ventricle beat together.

What the research shows

  • In some people with heart failure, electrical conduction is delayed, most often as left bundle branch block, so the ventricle walls contract out of step.
  • Cardiac resynchronisation therapy paces both sides so they contract together, improving pumping efficiency.
  • It improves symptoms, reduces hospital admission and prolongs life in selected patients, particularly those with a wide QRS and left bundle branch block.
  • Benefit is largest in those with a QRS above 150 milliseconds, and is less certain with a narrow QRS, where it may cause harm.
  • It is often combined with a defibrillator in one device.
  • Newer approaches pace the heart's own conduction system directly and are an alternative in some patients.

Why it matters

CRT is one of the few interventions in heart failure that makes people feel noticeably better and live longer at the same time.

What's still uncertain

  • How to select patients with intermediate QRS duration.
  • Whether conduction system pacing will replace conventional CRT.

Read more

Next: Fixing the plumbing

Part 3 of 5

Valve and coronary procedures

Review of many studies

What happens

Where something is mechanically wrong.

What the research shows

  • Severe aortic stenosis can be treated by surgical replacement or by catheter, and relieving it can resolve the heart failure.
  • Mitral regurgitation caused by a stretched ventricle can sometimes be reduced with a clip delivered by catheter, improving symptoms and admissions in selected patients.
  • Coronary bypass surgery may improve function where there is substantial viable but underperfused muscle.
  • Atrial fibrillation ablation improves outcomes in selected patients with heart failure, more than rate control alone in some trials.
  • These are assessed by a multidisciplinary heart team, because the decisions depend on the combination of problems rather than any one.
  • The common thread is identifying a mechanical problem that medicine can only compensate for.

Why it matters

The question the workup is really asking is whether there is something to fix. Where there is, the gain is far larger than any drug provides.

What's still uncertain

  • Which patients benefit most from mitral clip procedures.
  • How to select patients for ablation.

Read more

Next: Advanced therapies

Part 4 of 5

Pumps and transplant

Review of many studies

What happens

For a small, carefully selected group.

What the research shows

  • Advanced heart failure means persistent severe symptoms despite full treatment, often with repeated admissions and worsening kidney or liver function.
  • A left ventricular assist device is a mechanical pump implanted to support or replace the left ventricle's work, powered through a cable to an external controller and batteries.
  • It can be a bridge to transplant or a long-term therapy, and it substantially improves survival in advanced heart failure. Risks include bleeding, stroke, infection at the driveline and device thrombosis.
  • Heart transplantation offers the best outcomes for suitable candidates, limited by donor availability, with median survival now beyond a decade.
  • Transplant requires lifelong immunosuppression and intensive follow-up, and has strict eligibility criteria.
  • Referral should happen before a person becomes too unwell to be a candidate, which is why specialist referral at the first signs of advanced disease matters.

Why it matters

The commonest problem with advanced therapies is late referral. Candidacy closes as other organs fail, and that window is often missed.

What's still uncertain

  • How to improve timely referral for advanced therapies.
  • How to widen equitable access to transplant and LVAD.

Read more

Next: Palliative care

Part 5 of 5

Alongside, not instead

Review of many studies

What happens

Symptom control and planning.

What the research shows

  • Palliative care in heart failure means treating symptoms and supporting quality of life, and it runs alongside active treatment rather than replacing it.
  • It helps with breathlessness, fatigue, pain, appetite, anxiety and depression, all of which are common and under-treated in heart failure.
  • Early involvement improves quality of life and symptom burden in trials, and does not shorten life.
  • Advance care planning covers what matters to the person, their wishes about hospital admission and resuscitation, and deactivation of a defibrillator if they have one.
  • Heart failure has a less predictable trajectory than many cancers, with repeated deteriorations and recoveries, which is exactly why planning in advance helps.
  • Hospice care is a later and separate step, and is under-used in heart failure compared with cancer.

Why it matters

Palliative care is frequently introduced far too late in heart failure, because the trajectory never produces an obvious moment to raise it.

What's still uncertain

  • How best to time palliative referral given the unpredictable course.
  • Why hospice use remains low in heart failure.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.